Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 17/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960368 | 0.96 | PIK3CA (0.46) | PDE8BPIK3CAEPHX2 | |
| SCHEMBL2812486 | 0.82 | PDE8B (0.44) | PDE8B | |
| SCHEMBL21961347 | 0.80 | L3MBTL1 (0.40) | PIK3CA | |
| SCHEMBL21960839 | 0.80 | PDE8B (0.50) | PDE8BHTR2AHTR2CSLC6A4EPHX2 | |
| SCHEMBL21964573 | 0.78 | TSHR (0.44) | PDE8BPIK3CAEPHX2 | |
| SCHEMBL21960381 | 0.78 | TSHR (0.44) | PDE8BPIK3CAEPHX2 | |
| SCHEMBL21964574 | 0.78 | TSHR (0.44) | PDE8BPIK3CAEPHX2 | |
| SCHEMBL21960857 | 0.78 | SLC6A2 (0.39) | PDE8B | |
| SCHEMBL21961341 | 0.78 | SLC6A2 (0.39) | PDE8B | |
| SCHEMBL21960856 | 0.78 | SLC6A2 (0.39) | PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | PDE8B 3460/4885HTR2A 4746/4885HTR2C 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.